pharm edaily

[Shin-Min Joon, Edaily Reporter] Huons Group participated in a dermatology exhibition in Dubai Middle East unveiling the Group’s innovative products and cutting edge technologies to enhance global competitiveness.

Humedix, Huons Meditech and Huons Biopharma of Huons Group attended Dubai World Dermatology and Laser Conference and Exhibition, ‘Dubai Derma 2025’. The photo shows visitors examining products at Huons Group’s exhibition booth. (Image=Huons)

On April 17, Humedix (CEO Kang Min jong), Huons Meditech (CEO Lee Jin suk), and Huons BioPharma (CEO Kim Yeong mok) announced that the Group companies had participated in this year’s Dubai World Dermatology and Laser Conference & Exhibition, (Dubai Derma 2025), held this week from April 14~16 at Dubai World Trade Center Dubai United Arab Emirates.

Dubai Derma 2025 is the 24th edition of the largest dermatology professional gathering in the Middle East and North Africa (MENA). The event featured participation from leading companies and experts in the field of medical devices, aesthetics and cosmeceuticals (a combination of cosmetics and pharmaceuticals) and included conferences to promote the development of the skin care industry in the Middle East.

At the exhibition Humedix signed a supply contract for its famous hyaluronic acid (HA) filler, Elravie, covering Saudi Arabia, Lebanon and Syria establishing a bridgehead for expanding into the Middle Eastern market.

Elravie Premier is a filler that uses Humedix’s proprietary technology to maintain the viscosity of HA. Elravie has received product approval in Korea, the European Union (CE), China (NMPA: National Medical Products Administration), and Russia (RZN: Federal Service for Surveillance in Healthcare). Elravie is currently being exported to 19 countries, including China and Brazil.

CEO of Humedix Kang Min jong said “Elravie has already earned strong trust from Middle Eastern buyers thanks to its proven efficacy and safety. We plan to actively expand into the Middle Eastern market by advancing into Saudi Arabia, one of the region’s key markets.”

Huons Meditech received attention for ‘Dermashine Pro’ from buyers at the exhibition. ‘Dermashine Pro’ is an automatic mesotherapy injector equipped with an automatic pressure detection system, which injects high-molecular-weight hyaluronic acid into the entire face. Huons Meditech achieved cumulative sales of 20,000 units of the ‘Dermashine’ product series as of the end of 2024.

CEO of Huons Meditech Lee Jin-suk said “Dubai Derma 2025 opened up many new business opportunities for Huons Meditech, and we plan to expand into the global market. We will further strengthen our position in the global medical device market by enhancing overseas marketing.”

Huons BioPharma attracted significant attention from visitors for its botulinum toxin products and proprietary technology at the exhibition. Huons BioPharma has obtained product approval in 15 countries including Russia, Southeast Asia (Thailand, etc.), and the Middle East (Iraq, etc.) for its botulinum toxin and is currently in the process of obtaining product approval in China as well.

According to a company official “Leveraging our participation in Dubai Derma 2025 we will continue to highlight the competitive advantages of our product and secure strategic partnerships to expand our presence in the Middle East.”